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The main focus of a nation’s health system revolves
around the development of effective strategies and new
options of treatment, with the aim of preventing or even
reversing human diseases (1). The spectrum of disorders of
the brain, part of the central nervous system (CNS), is large,
covering hundreds of disorders that are listed in either the
mental or the neurological disorder chapters of established
international diagnostic classification systems. Brain dis-
orders account for the majority of short- and long-term
impairments and disabilities (2). As such, the best available
estimates of the prevalence and cost per person for 19
groups of brain disorders in Europe have been reported (2).
In brief, the total cost of brain disorders is estimated at J798
billion (2). Furthermore, the European per capita cost of
brain disorders is J1550 on average but varies by country
(2). The costs (in billion JPPP 2010) of the included brain
disorders are as follows: mood disorders J113.4; dementia:
J105.2; psychotic disorders: J93.9; anxiety disorders: J74.4;
addiction: J65.7; stroke: J64.1; headache: J43.5; mental
retardation: J43.3; sleep disorders: J35.4; traumatic brain
injury: J33.0; personality disorders: J27.3; child/adolescent
disorders: J21.3; somatoform disorder: J21.2; multiple
sclerosis: J14.6; Parkinson’s disease: J13.9; epilepsy:
J13.82; neuromuscular disorders: J7.7; brain tumor: J5.2
and eating disorders: J0.8 (2).
Leading scientific journals and primary funding agencies
suggest that neuroscience is the most rapidly growing field
within the biomedical sciences in the world (1). For Latin
American countries, especially Brazil, these assertions are
especially relevant. For example, Nitrini conducted a study
in 2006 that assessed the evolution of scientific production
by 295 Brazilian clinical neuroscientists from 1995 to 2004
(3). The author showed that more than 40% of the Brazilian
papers were published in Arquivos de Neuro-Psiquiatria,
the official journal of the Brazilian Academy of Neurology,
and that epilepsy was one of the sub-areas with the highest
scientific production (3). The growing number of publica-
tions on epilepsy detected in this study may be a
consequence of several well-established factors. By defini-
tion, epilepsy is a transient occurrence of signs and/or
symptoms due to abnormal, excessive, or synchronous
neuronal activity in the brain (4). Furthermore, epilepsy is
considered to be the most common serious neurological
condition. Epilepsy knows no geographic, social, or racial
boundaries, it occurs in both men and women, and it affects
people of all ages, though it more frequently affects young
people in the first two decades of life and people over the
age of 60 (5,6). Epilepsy has a prevalence of approximately
1% in developed countries; each year, 24 per 100,000
persons suffer from this neurological condition in Europe
and 53 per 100,000 in North America (1,3,7-9). The incidence
of epilepsy is higher in developing countries compared to
industrialized countries, with up to 190 affected individuals
per 100,000 people (10,11). Epilepsy is considered a serious
chronic disease, with a number of factors that negatively
affect the quality of life of these individuals. Stigma and
exclusion have become common global features of epilepsy
(5,12,13). In addition, physical, psychological, and social
consequences are very severe, as seizures may cause fear,
misunderstanding, secrecy, stigmatization, and social isola-
tion (5,12,13).
Additionally, we must not fail to mention that, unfortu-
nately, epilepsy is associated with a high rate of premature
death compared with the general population (14,15).
Sudden unexpected death in epilepsy (SUDEP) is the most
common epilepsy-related category of death, accounting for
7.5% to 17% of all deaths in people with epilepsy and 1:500
to 1:1,000 patient-years among adults (14-18). The main risk
factors described thus far are the presence or number of
generalized tonic–clonic seizures (GTCS), nocturnal sei-
zures, young age at epilepsy onset, long duration of
epilepsy, dementia, the absence of cerebrovascular disease,
asthma, male gender, the symptomatic etiology of epilepsy,
and alcohol abuse (14,15,18-21). Regarding epilepsy causal
factors, experimental and clinical studies suggest that
respiratory and cardiovascular abnormalities during and
after seizures and genetic factors likely contribute to SUPEP
risk (19,20,22-27). Obviously, it is extremely difficult to
estimate SUDEP occurrence. However, discovery and care-
ful evaluation of new risk factors, greater specificity
regarding mechanisms, and the development of effective
preventive measures may help prevent the occurrence of
fatal events in affected individuals. Along these lines,
proposals for future research that expand on existing
clinical, genetic, and basic science research and that support
the education of health care practitioners and people with
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epilepsy will be of great value for advancing our under-
standing of SUDEP and, ultimately, our capacity to prevent
it (28,29).
Despite the effort, dedication, and enthusiasm of all
neuroscientists, we are not yet fully prepared to implement
all of the proposals suggested thus far. For example, one
area that merits further consideration is whether and when
to talk about SUDEP with patients, family members, and
caregivers. Although epileptologists have not yet estab-
lished a global consensus on this subject (30,31), recent
studies suggest that providing information about SUDEP to
individuals, relatives, and caregivers is most likely more
beneficial than harmful in most cases (32). We recently
evaluated a survey of the current practice of all 293
epileptologists officially accredited at the Brazilian League
of Epilepsy (LBE) (33). Unfortunately, the participation rate
was very low, as only 44 professionals answered the
questions (33). Of these, 14% of epileptologists discussed
SUDEP risk with the majority of their patients, 76% with a
minority of their patients, and 10% with none (33).
Interestingly, of all such professionals who discuss SUDEP
with a minority of their patients, approximately half of them
(44%) discussed the possible occurrence of SUDEP when
patients asked about it (33). It should be noted that although
the data obtained in our study are consistent with the
current literature, the low participation of Brazilian epilep-
tologists in our assessment is an issue that should be
reviewed and discussed. This disinterest becomes more
worrisome when we evaluate the report recently developed
by the Brazilian Federal Council of Medicine (34) (Figure 1).
In brief, the report notes that Brazil has a total of 2629
neurologists, the vast majority of whom (approximately
80%) are concentrated in the south and southeast parts of
Brazil. Thus, a number of questions must be answered: 1 –
How can individuals with epilepsy in regions with
extremely low numbers of neurologists be monitored and
treated? 2 – How can campaigns be created in these regions
to demystify and reduce the stigma that exists against people
with epilepsy? 3 – Is it possible to create tertiary epilepsy
centers in regions with low numbers of neurologists? 4 - How
Figure 1 - Absolute numbers of neurologists in Brazil; obtained from the Report of Medical Demography in Brazil - General Data and
Descriptions of Inequalities, Volume 1 (Brazilian Federal Council of Medicine; Regional Council of Medicine of Sa˜o Paulo, December
2011).
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can we create research institutes in these regions? 5 – Can
discussions regarding SUDEP take place with these profes-
sionals? Despite the existing difficulties, the vast majority of
epileptologists located in the south and southeast actively
participate in experimental and clinical epilepsy studies,
including SUDEP. In this regard, this series of questions and
proposals could stimulate the 293 accredited epileptologists
in LBE to create an intense task force in poorer regions. We
realize that this venture is not easy, but it is certainly feasible.
We have qualified and credentialed professionals that are
ready to initiate and invest in collaborations. With sustained
focus and fundraising for epilepsy and SUDEP research in
both children and adults, the future is very promising (28). As
the American physicist Robert Hutchings Goddard said:
‘‘Just remember - when you think all is lost, the future
remains’’.
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